Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 6/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7806789 | 0.65 | SLC6A3 (0.44) | CYP1A2CYP2C9KCNH2 | |
| SCHEMBL8193438 | 0.64 | — | — | |
| SCHEMBL4979111 | 0.61 | OPRD1 (0.37) | — | |
| SCHEMBL7265277 | 0.61 | LMNA (0.39) | — | |
| SCHEMBL17433855 | 0.61 | MAPT (0.45) | NCF1BACE1ACHETSHR | |
| SCHEMBL17433982 | 0.60 | BACE1 (0.44) | NCF1BACE1TSHRALDH1A1 | |
| SCHEMBL17434303 | 0.60 | TSHR (0.51) | NCF1TSHRALDH1A1 | |
| SCHEMBL17433817 | 0.60 | TSHR (0.51) | NCF1TSHRALDH1A1 | |
| SCHEMBL17433814 | 0.60 | TSHR (0.51) | NCF1TSHRALDH1A1 | |
| SCHEMBL26695128 | 0.58 | BACE1 (0.61) | NCF1BACE1ACHECYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095591-B2 | Pharmaceutical composition for use in the treatment of glaucoma | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-08-04 | — | — | US | disclosed |
| US-20130172370-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GLAUCOMA | VT IDIRECT ,INC. (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2585071-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GLAUCOMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012000904-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GLAUCOMA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172370-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GLAUCOMA | CXCR3, CCR5, CCR7 | NCF1 2928/4885BACE1 3459/4885BCHE 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.